Oxaliplatin drug data and news

---

Tarceva Alone Has Palliative Effects in Patients With Metastatic ...  16 May 2006
...cancer. Tarceva has been added to other agents such as Xeloda (capecitabine) and Eloxatin (oxaliplatin) (see related news). However ... - Cancer Consultants (press release),

Steady Gains Made Against Digestive Cancers  May 15, 2006
One study found that adding the drug oxaliplatin to standard chemotherapy regimens in individuals with stage II or III colorectal cancer reduced the relative ... - PakTribune.com,

Colorectal cancer treated by oxaliplatin and 5-fluorouracil with ...  Apr 19, 2006
2006 APR 19 - (NewsRx.com) -- Colorectal cancer could be treated by oxaliplatin and 5-fluorouracil (5-FU) with leucovorin. "Oxaliplatin ... - Therapeutics Daily (subscription) (press release),

Colorectal cancer treating it - A moral and legal dilemma  May 15, 2006
...medication. Ontario and Alberta are also not paying for one of the most standard of treatments, Oxaliplatin (eloxatin). Patients ... - Canada NewsWire (press release),

NeoRx Initiates Clinical Trial of Picoplatin in Colorectal Cancer ...  May 10, 2006
In the treatment of metastatic colorectal cancer, treatment with fluorouracil and leucovorin plus oxaliplatin (Eloxatin(R)) (known as the FOLFOX regimen) is ... - PharmaLive.com (press release),

Pro-Pharmaceuticals to Present Corporate Update at Rodman & ...  May 9, 2006
...multi-center, randomized clinical trial to evaluate the safety and efficacy of DAVANAT(R) with 5-FU and leucovorin in combination with irinotecan or oxaliplatin ... - Genetic Engineering News,

Sirtex begins liver cancer combo trial  May 9, 2006
..."We know from previous clinical trials that it is safe to combine SIR-Spheres microspheres with oxaliplatin and irinotecan chemotherapy," said Dr David Cade ... - Pharmaceutical Business Review

Chemotherapy regimen predicts steatohepatitis and an increase in ...  May 3, 2006
The other most commonly used chemotherapy drug, oxaliplatin, produced sinusoidal dilation (swelling and leaking of blood vessels in the liver) in almost 19 ... - News-Medical.net,

Sirtex Announces Clinical Trial Evaluating the Use of SIR-Spheres ...  May 8, 2006
..."We know from previous clinical trials that it is safe to combine SIR-Spheres microspheres with Oxaliplatin and Irinotecan chemotherapy," says Dr. David Cade ... - Genetic Engineering News,

European Study Suggests Xeloda® is Cost Effective Compared to 5 ...  May 2, 2006
...colorectal cancer. Xeloda and Eloxatin® (oxaliplatin) is an effective treatment regimen for Dukes’ C colon cancer. The purpose ... - Cancer Consultants (press release),

NICE Says Yes To ‘no Wait' Oral Bowel Cancer Treatment Xeloda® ...  Apr 27, 2006
NICE also recommends the use of oxaliplatin in combination with 5-FU for post-operative use in bowel cancer, giving patients and clinicians greater choice than ... - Medical News Today (press release),

Fatty Inflammation of the Liver Linked with Worse Outcomes After ...  May 8, 2006
Patients who received a chemotherapy regimen that included oxaliplatin were more likely to develop sinusoidal dilation (swelling of blood vessels in the liver ... - Cancer Consultants (press release),

Xeloda®, Eloxatin®, and Tarceva® Effective for Previously ...  Apr 19, 2006
...recently published in the Journal of Clinical Oncology, the treatment combination consisting of Xeloda® (capecitabine), Eloxatin® (oxaliplatin), and Tarceva ... - Cancer Consultants (press release),

Sirtex to test microspheres with Xeloda  May 8, 2006
...in the combination. The company said its treatment has already tested safe with oxaliplatin and irinotecan chemotherapy. "We also ... - United Press International

Amgen's First Quarter 2006 Adjusted Earnings per Share, Excluding ...  Apr 20, 2006
The potential indication is for the treatment of metastatic colorectal cancer in patients who have failed prior chemotherapy, including oxaliplatin- and/or ... - Webbolt Business News,

Chemotherapy a necessary evil for many cancer patients  Apr 27, 2006
The three chemo drugs are 5-FU (an abbreviated euphemism for stronger words, according to some patients), leucovorin and oxaliplatin (my personal demon). ... - 2TheAdvocate,

Xeloda®, Eloxatin® and Tarceva® Effective for Previously ...  Apr 28, 2006
Researchers from the Dana Farber Cancer Center have reported that the combination of oral Xeloda (capecitabine), intravenous Eloxatin (oxaliplatin) and oral ... - Cancer Consultants (press release),

XELOX Is Well Tolerated First-Line Regimen for Elderly Patients ...  Apr 24, 2006
Researchers from Spain have reported that the combination of Xeloda® (capecitabine) and Eloxatin® (oxaliplatin) known as XELOX is a well tolerated regimen ... - Cancer Consultants (press release),

Chugai Files Innovative Cancer Medicine Avastin for Fast Approval ...  Apr 21, 2006
Group (ECOG), Avastin was also shown to significantly improve survival when added to another widely prescribed chemotherapy regimen (oxaliplatin/5-fluorouracil ... - PharmaLive.com (press release),

Camptosar® and Eloxatin® Safe and Effective for Initial ...  Apr 25, 2006
Researchers from MD Anderson Cancer Center have reported that the combination of Camptosar (irinotecan) and Eloxatin (oxaliplatin) is an effective drug ... - Cancer Consultants (press release),

Gemzar®/Eloxatin®/Avastin® Promising for Advanced Liver Cancer  Apr 20, 2006
...recently published in the Journal of Clinical Oncology, the treatment combination consisting of Gemzar® (gemcitabine), Eloxatin® (oxaliplatin), and Avastin ... - Cancer Consultants (press release),

No specific cytochrome P450-based drug interaction studies have been conducted. No pharmacokinetic interaction between 85 mg/m² ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m² ELOXATIN dosed every 3 weeks. Since platinum containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; although, this has not been specifically studied.